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Abstract
The rates of immunologic and clinical progression are lower in patients with drug-resistant HIV compared to wild-type HIV.
This difference is not fully explained by viral load. It has been argued that reductions in T cell activation and/or viral fitness
might result in preserved target cells and an altered relationship between the level of viremia and the rate of CD4+ T cell
loss. We tested this hypothesis over time in a cohort of patients with highly resistant HIV. Fifty-four antiretroviral-treated
patients with multi-drug resistant HIV and detectable plasma HIV RNA were followed longitudinally. CD4+ T cell counts and
HIV RNA levels were measured every 4 weeks and T cell activation (CD38/HLA-DR) was measured every 16 weeks. We found
that the levels of CD4+ T cell activation over time were a strong independent predictor of CD4+ T cell counts while CD8+ T
cell activation was more strongly associated with viremia. Using spectral analysis, we found strong evidence for oscillatory
(or cyclic) behavior in CD4+ T cell counts, HIV RNA levels, and T cell activation. Each of the cell populations exhibited an
oscillatory behavior with similar frequencies. Collectively, these data suggest that there may be a mechanistic link between
T cell activation, CD4+ T cell counts, and viremia and lends support for the hypothesis of altered predator-prey dynamics as
a possible explanation of the stability of CD4+ T cell counts in the presence of sustained multi-drug resistant viremia.
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Introduction
Current therapeutic strategies for HIV-infected persons include
the use of antiretroviral therapy to fully inhibit viral replication, as
defined by achieving and maintaining undetectable plasma HIV
RNA levels. The vast majority of patients who are treatment naı¨ve
and able to adhere to a recommended regimen are able to achieve
durable and perhaps indefinite viral suppression. A poorly
described but significant subset, however, are not able to achieve
this outcome, either due to pre-existing resistance and/or the
inability to fully adhere to therapy. Most, but not all, of these
patients eventually develop drug resistance mutations and, hence,
have limited long-term options for complete viral suppression.
The natural history of incomplete or partial viral suppression
with combination therapy is complex. As compared to untreated
disease, those who remain on a stable regimen despite the presence
of drug-resistance mutations have slower rates of CD4+ T cell
decline and a lower risk of progressing to AIDS and/or death
[1,2,3]. This effect appears to be more strongly associated with
failure of protease inhibitor-based regimens than with failure of
non-nucleoside reverse transcriptase inhibitor based regimens
[1,4]. Although partial reduction in viral load clearly contributes
to the residual benefit of therapy [5], the delayed risk of disease
progression in treated versus untreated disease remains significant,
even after controlling for viral load [1,2].
Among untreated individuals, the level of viremia is only
partially predictive of the rate of disease progression, as defined by
the rate of CD4+ T cell loss and/or by the risk of progressing to
AIDS and death [6,7]. T cell activation (as defined by expression
of CD38 and HLA-DR) is an independent predictor of CD4+ T
cell loss and disease progression among untreated patients [8,9].
Theoretically, activated T cells may contribute to a poor prognosis
by supporting higher levels of viral replication and/or by causing
inflammation-associated damage to the immune system and other
organ systems. Given the central role of T cell activation in
untreated diseases our previous work explored the impact of drug-
resistance on the complex relationship between T cell activation
and viral load. We have found that, after controlling for the levels
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of viremia, CD8+ T cell activation was lower in those with drug
resistance than those with wild-type HIV. This effect appeared to
be more strongly associated with the presence of protease inhibitor
resistance rather than direct exposure to the immunomodulatory
effects of protease inhibitors [10].
To understand the role of the T cell activation, progressive
immunodeficiency, and drug resistant HIV, we performed detailed
immunologic and virologic measurements among a cohort of
treated patients with detectable viremia who were maintained on a
stable regimen pending more effective therapeutic options. The
overall objectives of this prospective cohort were to determine the
impact of replicative capacity, T cell activation and HIV-specific T
cell response on both viremia and peripheral CD4+ T cell counts
over time. In the current analysis, we describe how many of these
factors evolve over time. We found that CD4+ T cell activation
was most strongly associated with the CD4+ T cell counts while
CD8+ T cell activation was more strongly associated with viremia.
Spectral analysis [11] in a subset of subjects revealed evidence of
oscillatory behavior in CD4+ T cell counts, CD4+ T cell
activation, CD8+ T cell activation, and plasma HIV RNA levels.
Taken together, the data suggest a mechanistic link between T cell
activation, viremia and CD4+ T cell depletion and support the
hypothesis of altered predator-prey dynamics as a possible
explanation for the stability of CD4+ T cell counts even in the
present of sustained multi-drug-resistant viremia.
Materials and Methods
Subjects
All subjects were enrolled in the Partial Controllers on
Antiretroviral Therapy cohort (PCAT) [12]. All subjects provided
written informed consent. The study was approved by the
University of California, San Francisco Human Research
Protection Program Committee on Human Research, Laurel
Heights Panel. Eligibility criteria included having a detectable viral
load between 200 and 10,000 copies/mL while on a stable
optimized combination antiretroviral regimen. Subjects were
enrolled and followed in the period prior to the widespread
availability of integrase inhibitors, CCR5 inhibitors, and second
generation non-nucleoside reverse transcriptase inhibitors, and
had hence had limited options for complete viral suppression.
Because of concerns that high level viremia (.10,000 copies
RNA/mL) would pose substantial risk to the study participant,
subjects were encouraged to consider treatment modification once
viral loads increased above this level. We chose a threshold of
10,000 copies of HIV RNA/mL (using the bDNA method) for this
study because previous data suggested that viral loads above this
threshold might be associated with rapid CD4+ T cell loss. Given
this data, we felt that subjects and their health care providers
should have no perceived barriers to modifying therapy. For the
current analysis, subjects were censored if their HIV RNA levels
exceeded this threshold on two subsequent visits or if the
optimized antiretroviral therapy was modified or discontinued.
Immunologic and virologic measurements
Viral load and CD4+ T cell counts were measured every 4
weeks. T cell activation (CD38+/HLA-DR+) was measured every
16 weeks using cytokine flow cytometry, as previously described
[12]. HIV replicative capacity was also measured longitudinally,
using a modified version of an HIV phenotypic drug susceptibility
assay (Monogram Biosciences). Briefly, HIV RNA was extracted
from the subject’s plasma and the terminal 18 codons of the gag
gene, the entire pro gene, and a portion of the RT gene were PCR
amplified. The amplified gene segments were inserted into a viral
vector containing a luciferase gene. Following a single round of
viral replication in the absence of drug, luciferase activity was
measured and compared to that for a reference virus (NL4-3).
Statistical analysis
The primary variables considered for modeling CD4+ T cell
counts over time included CD4+ and CD8+ T cell activation,
CD4 nadir, duration of infection, HIV-specific T cell response,
viral burden, and viral replication capacity. Plotting revealed
significant skews in the distributions of CD4+ T cell counts,
CD4+ and CD8+ T cell activation, and plasma HIV RNA levels,
and these values were log10 transformed to meet model
assumptions. Given the less frequent measurements of immune
activation than CD4+ T cell counts, CD8+ T cell counts, and
viral load, we used multiple imputation to address the missingness
in the T cell activation and replication capacity data. Missing
data can lead to bias in estimates as well as a loss of power
[13,14,15]. The extent of the bias depends on the cause of the
missingness. Multiple imputation can be used when the missing
data are ‘‘missing at random’’, that is the probability of the
observation being missing for a particular subject does not
depend on the value of the marker, conditional on other observed
variables. In this case the assumption was justified in that it was
solely a cost issue related to the missingness and not an
underlying disease process. Multiple imputation has been used
successfully in a wide variety of fields of application from
astrophysics [16] to chemistry [17] to clinical research
[13,14,15,18]. Multiple imputation has not only been used in
regression settings but also used in spectral analysis [16,17,19].
Instead of filling in a single value for each missing value, such as
last observation carried forward (LOCF), multiple imputation
replaces each value with a set of draws from a random sample of
plausible values reflecting the uncertainty of the missing values
[18]. In this way, one creates multiple datasets, each with
different draws from the random sample of the missing values
resulting in multiple complete case datasets. Standard statistical
techniques can then be applied to each complete case imputed
dataset and the results are then combined for the final inference.
We used PROC MI in SAS version 9.2 for multiple imputation,
using the Markov Chain Monte Carlo (MCMC method) with
multiple chains. We discarded the first 8000 iterations as ‘‘burn
in’’ and used a total of 10000 iterations for inference. We used the
Jeffries (noninformative) prior and took the results of the
Expectation-Maximization (EM) algorithm as our starting point.
For the multiple imputed estimates, time-series and autocorrela-
tion plots showed that our MCMC sampler was mixing well and
that the estimates reached convergence. We then used linear
mixed models with random intercepts and slopes to assess the
association of T cell activation and viremia in CD4+ T cell counts
over time in each imputed dataset. An unstructured covariance
matrix was used to assess the serial correlation. This approach
allows one to model the association of continuous predictor
variables measured longitudinally on a continuous longitudinal
outcome variable while accounting for within-subject correla-
tions.
We also measured relative efficiency, which is a function of the
number of imputations, m, and the percent missingness of the data.
It is defined in units of variance as the differential utility of using m
(in this case m=30) imputations instead of an infinite number of
imputations, where 100% is fully efficient. We conducted 30
imputations because results have shown that although the estimate
is unbiased, more imputations are needed than previously
suggested to attain good statistical power [20]. SAS Proc
Oscillatory Patterns in Chronic HIV Infection
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MIAnalyze was used for statistical inference of parameters from
the 30 imputed complete datasets.
Spectral analysis
Individual viral and immune cell dynamics were analyzed using
spectral analysis [11] in a subset of subjects. Subjects with at least
20 observation points for all compartments (i.e., CD4+ T cell
counts, HIV viremia, and T cell activation) were included for
analysis (N= 11). Spectral analysis can be used to detect cyclical
patterns in data, with the purpose of decomposing complex time
series with cyclical components into sinusoidal functions. In a
sense, performing spectral analysis on time series data can be
compared to putting these data through a prism that identifies the
underlying cyclical (sinusoidal) components. As a result, data that
might initially look like random noise can be meaningfully
interpreted in terms of underlying recurring cycles. The
decomposition is performed using the Fourier transform. The
time series can then be presented as a mixture of functions
expressed as y~amplitude  sin(2  p  frequency  timezphase).
The phase is determined by the initial displacement of the wave at
time t = 0. In this case the y would be the population of interest such
as viremia. Amplitude is the maximum height of the wave (in
absolute value). Frequency is the reciprocal of the period which is
the length of time for the wave to repeat. This signal is thus
presented in the frequency domain, where frequency is expressed in
units of [1/time] and significant peaks are recorded. Raw data are
first de-trended (the mean and the linear fit are subtracted) and then
the Lomb-Scargle periodogram is constructed. This algorithm
generates a Fourier spectrum for data that are not equally spaced
[21]. Signals with peaks below the 50% critical limit were discarded.
For this analysis, spectral decomposition was used to determine
signal composition for HIV RNA levels, CD4+ T cell activation,
CD8+ T cell activation, and CD4+ T cell counts. From the analysis,
we determined each signal from noise, identified the presence of
oscillatory behavior, and drew conclusions about correlations
between the populations. The results show the averages of the
quantities of interest average across all imputations.
While spectral analysis can only examine one patient over time,
non-linear mixed models can examine all subjects simultaneously.
We therefore constructed a non-linear mixed effects model with a
random intercept to model log viremia over time. To model the
oscillatory trend, we used a mixture of two sine waves with
frequencies at 2p and 8p, as suggested by the results of the spectral
analysis, to account for any cyclical patterns in the data. We fit a
non-linear mixed effects model with random intercept model using
the first-order method of Beal and Sheiner [22] that included an
indicator for protease inhibitor use, CD8+ T cell activation,
baseline viremia, the oscillatory component and an interaction for
the oscillatory component and protease inhibitor use. Estimates
from the spectral analysis were used as the starting values.
Results
We examined 54 subjects with partially controlled antiretrovi-
ral-resistant viremia on a stable antiretroviral regimen. There were
50 men (93%) and 4 women. The median baseline CD4+ T cell
count was 303 cells/mm3 (IQR: 210–437) and the median log10
plasma HIV RNA level was 3.3 copies/ml (IQR: 2.5–3.7)
(Table 1). The baseline percent of activated CD38+HLA-DR+
CD4+ T cells was 6.4% (IQR: 5.0–8.9) and the baseline percent of
activated CD38+HLA-DR+ CD8+ T-cells was 21.1% (IQR:
15.1–30.0). The median self-reported CD4 nadir was 82 cells/
mm3 (IQR: 20–164). Forty (74%) of the subjects were failing on a
protease-inhibitor based regimen. Of those, 30 (75%) were failing
a boosted protease inhibitor regimen. The median duration of
follow-up was 44 weeks (IQR 18.1 to 71.0). Across all subjects, the
average rate of CD4+ T cell change was 21 CD4+ T cells/mm3/
month. Of interest, CD4+ T cell counts increased, on average, by
20 cells/mm3 from baseline in subjects taking boosted protease
inhibitors, and decreased by 33 cells/mm3 in subjects not taking
these drugs, although this difference did not reach statistical
significance.
As expected, at baseline there was a negative correlation
between log10 viral load and CD4+ T cell count (rho=20.28,
p = 0.038). There was also a negative correlation between T cell
activation and CD4+ T cell counts with subjects with higher levels
of T cell activation having lower CD4+ T cell counts at baseline
(rho=20.38, p = 0.006 for CD4+ T cell activation and
rho=20.30, p = 0.03 for CD8 T cell activation). Log10 viremia
and both CD4+ and CD8+ T cell activation were strongly
correlated (rho= 0.35, p = 0.012 and rho= 0.52, p = 0.0001
respectively). The strong association between log10 viremia and
CD8 activation persisted across time.
Longitudinal predictors of CD4+ T cell counts and
viremia
We analyzed longitudinal CD4+ T cell counts using a mixed
effects model with a random intercept and slope. Correlation over
time was modeled using an unstructured covariance matrix. Not
surprisingly, CD4+ T cell counts declined over time (adjusted p-
value 0.0028). Across all subjects, higher levels of CD4+ T cell
counts were temporally associated with lower CD4+ T cell
activation, after adjusting for the log plasma HIV RNA levels. For
every percentage increase in CD4+ T cell activation, CD4+ T cell
counts declined by 2 cells/mm3 (adjusted p-value of 0.025;
Table 2). Similarly, higher replication capacity was associated with
lower CD4+ T cell counts (adjusted p-value 0.041). This effect of
Table 1. Baseline characteristics of the study group.
Baseline variable Median Interquartile range
Age in years 46 42–52
CD4 T+cell, cells/mm3 303 210–437
Plasma HIV RNA log 10 copies/ml 3.3 2.5–3.7
CD4 activation (%) 6.4 5–8.9
CD8 activation (%) 21.1 15.1–30.0
CD4 nadir, cells/mm3 82 20–164
Follow up (weeks) 44 18.1–71.0
N Percent
Gender
Male 50 93
Female 4 7
Protease Inhibitor (PI)
Boosted 30 55
RTV/LPV 23 43
RTV+other PI 7 13
Non-boosted 10 19
None 14 26
Non-nucleoside RTI 7 13
Nucleoside RTI 53 98
doi:10.1371/journal.pone.0021190.t001
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CD4+ T cell activation on CD4+ T cell counts was significant in
the complete case analysis (data not shown) and remained
significant across all multiply imputed datasets. Table 2 gives the
estimates from the final mixed effects model as well as the relative
efficiencies of the multiple imputation estimates.
Longitudinal predictors of viremia
We analyzed longitudinal plasma HIV RNA levels using a
mixed effects model with random intercepts and slopes and an
unstructured covariance matrix. Across all subjects, higher levels
of plasma HIV RNA levels were temporally associated with lower
CD8 T cell activation. For every percentage increase in CD8 T
cell activation, log transformed plasma HIV RNA levels increased
by 0.02 logs (adjusted P-value,0.0001; Table 3). There was no
consistent relationship between replicative capacity and plasma
HIV RNA levels. This effect of CD8 T cell activation on plasma
HIV RNA levels was significant in the complete case analysis (data
not shown) and remained significant across all multiply imputed
datasets.
Immunologic and virologic measures follow an
oscillatory pattern
Next, we examined the correlation structure between CD4+ T
cells, T cell activation and viral burden over time in eleven subjects
using spectral analysis. Spectral analysis allows for modeling the
time series of each population as a mixture of sine waves. Each
time series was decomposed into a collection of sine waves with
different frequencies, amplitude, and phases.
Table 4 lists the demographic characteristics of the subjects
included in this analysis. Subjects in this subset did not differ
significantly from subjects not included in this analysis in terms of
average level of T cell activation, viremia or CD4+ T cell count. In
these eleven subjects we found evidence of oscillatory patterns in
the CD4 compartment with subjects exhibiting 2–6 separate
waves. Figure 1 shows, for a representative patient, the results from
the spectral analysis in terms of T cell activation, log viremia and
CD4 counts over time. Using mixed effects models with a
compound symmetric correlation structure, we found that subjects
with higher levels of CD4+ T cell counts over time had fewer CD4
waves and these waves had lower amplitudes (p = 0.0100 and
p= 0.0144 respectively). Similarly, we found cyclical behavior in
the T cell activation compartments. Subjects with higher levels of
viremia had higher amplitudes of CD8 activation (p,0.0001) and
lower phase shifts (p = 0.0001) controlling for CD4 nadir. We
found a tight correlation between viremia amplitude and CD8+ T
cell activation amplitude (rho= 0.61, p = 0.04). Take together this
yields further evidence of the mechanistic linkage between viremia
and CD8 T cell activation. Figure 2 plots, for four representative
patients, log CD8 activation and log viremia over time.
Overall, we found strong evidence of complex dynamics, with
subjects exhibiting 0 to 7 separate sine waves and with different
frequencies for each component. One or greater sine waves is an
indication of the presence of oscillatory behavior in activated
CD4+ T cells, activated CD8+ T cells, plasma HIV RNA levels,
and total CD4+ T cells. Tables 5–8 list, for each subject and each
parameter the average of the wave parameters (frequency,
amplitude and phase) as well as the total number of waves in
the model for CD8 T cell activation, HIV viremia, CD4 activation
and CD4 T cell counts respectively. Two subjects did not exhibit
oscillatory behavior in viremia. These two subjects also had the
lowest CD4 nadirs in the sample with nadirs of 2 and 24 cells/
mm3). These subjects were also amongst those with the highest
maximum viremia. However these subjects did not differ
significantly from other subjects in terms of length of follow-up,
average CD4+ count or average viremia.
To examine the determinants of oscillatory behavior in these
subjects, we constructed a non-linear mixed effects model with
random intercepts. We found evidence of an interaction with
protease inhibitor use and oscillatory behavior. Subjects who were
not on a protease-inhibitor containing regimen had a stronger
Table 2. Parameters associated with CD4 T cell count loss among patients with partially-controlled drug resistant viremia using a
mixed effects model.
Effect Estimate Standard Error 95% CI P Relative efficiency
Intercept 437 31.8 (375, 500) ,0.0001 0.996
Time (weeks) 20.356 0.119 (20.59, 20.123) 0.0028 0.998
Replication capacity 20.365 0.174 (20.715, 20.015) 0.0412 0.975
CD4 activation 21.695 0.742 (23.168, 20.222) 0.0246 0.981
Log viral load 219.95 6.131 (232.05, 27.85) 0.0014 0.987
The model shows that CD4 T cell count decreased over time. Across all subjects higher levels of CD4 T cell activation were associated with lower levels of CD4 T cell
counts controlling for log plasma HIV-1 viremia. Higher replication capacity was also associated with lower CD4 counts.
doi:10.1371/journal.pone.0021190.t002
Table 3. Parameters associated with log HIV viremia among patients with partially controlled drug resistant viremia using a mixed-
effects model.
Effect Estimate Standard Error 95% CI P Relative efficiency
Intercept 2.81 0.122 (2.57, 3.05) ,0.0001 0.99
Time (weeks) 20.002 0.0017 (20.005, 0.001) 0.232 0.997
CD8 activation 0.018 0.0036 (0.010, 0.025) ,0.0001 0.976
The model suggests that increases in CD8 T cell activation was associated with increases in log HIV viremia.
doi:10.1371/journal.pone.0021190.t003
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oscillatory signal than subjects on a protease-inhibitor containing
regimen (p= 0.04). In this model CD8+ T cell activation remained
a significant predictor of HIV viremia over time (p = 0.0007).
Table 9 lists the parameter estimates for this model.
Discussion
T cell activation is a central component of HIV and SIV
infection. Among untreated HIV-infected persons, measures of T
cell activation predict risk of subsequent disease progression
[23,24]. Among treated subjects, T cell activation is associated
with CD4+ T cell count changes during therapy, at least cross-
sectionally [10,25]. T cell activation rather than viral load appears
to be the primary characteristic that defines pathogenic versus
non-pathogenic SIV infection in non-human primate models [26].
Despite extensive investigation, the temporal associations between
immune activation, viral load, and peripheral CD4+ T cell counts
have not been fully defined. Here, we examined a unique cohort of
HIV-infected persons in which immune activation was thought to
have a strong independent effect on disease outcomes, and
measured changes in several relevant biologic outcomes over time.
We found that, among treated subjects with low levels of
detectable drug-resistant viremia (,10,000 copies/mL), higher
CD4+ T cell counts were predicted by lower levels of CD4+ T cell
Table 4. Demographic profile of patients included in the spectral analysis.
Patient
Maximum CD4
T cell count
(cells/mm3)
Average CD4
T-cell count
(cells/mm3)
CD4 nadir
(cells/mm3)
Maximum HIV-1
RNA (copies/mL)
Average HIV-1
RNA (copies/mL)
2004 310 228 2 4.65 2.92
3025 412 273 39 3.78 3.1
3035 319 225 60 3.66 3.24
3037 364 258 220 4.21 3.79
3040 481 365 90 4.27 3.97
3042 232 145 69 4.21 2.97
3077 445 293 285 3.84 3.35
3089 567 376 150 4.11 2.542
3102 420 254 24 4.86 3.95
3135 644 433 250 4.12 2.97
3153 462 356 274 4.78 4.2
doi:10.1371/journal.pone.0021190.t004
Figure 1. Complex oscillatory behavior in a representative patient. Changes in percent CD4 activation, percent CD8 activation and HIV
viremia over time using spectral analysis. Log HIV viremia is in red, CD8 activation is shown with dashed black lines and CD4 activation is shown with
the black solid line. Time is in days.
doi:10.1371/journal.pone.0021190.g001
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activation. In contrast, higher plasma HIV RNA levels were more
strongly predicted by higher levels of CD8 T cell activation. We
also observed that replication capacity, measured by an in vitro
assay, was associated with lower CD4+ T cell counts but not with
the level of viremia. Using a sophisticated statistical method that
seeks to define the temporal cause and effect association of these
Figure 2. Log viremia and Log CD8 activation over time in 4 patients. Log Viremia (lvl) is shown red and log CD8 activation is in black. Lines
were formed using a spline interpolation algorithm.
doi:10.1371/journal.pone.0021190.g002
Table 5. Spectral analysis estimated parameters for CD8 T cell activation.
CD8 T cell activation
Patient Number of waves Mean Frequency Std Dev Mean Amplitude Std Dev Mean Phase Std Dev
2004 3 0.059 0.039 8.710 1.274 3.163 0.518
3025 3 0.105 0.011 5.838 1.500 2.744 1.999
3035 5 0.067 0.038 5.038 1.833 1.795 1.463
3037 2 0.086 0.077 5.213 3.135 3.738 1.236
3040 4 0.061 0.043 4.543 5.630 2.167 0.658
3042 4 0.018 0.009 42.990 45.323 3.320 2.573
3077 4 0.078 0.062 31.924 21.029 4.064 1.675
3089 3 0.092 0.028 5.354 1.560 2.833 2.128
3102 4 0.073 0.024 16.464 9.540 2.350 1.476
3135 4 0.044 0.024 34.648 32.257 2.643 2.493
3153 3 0.073 0.022 42.089 36.380 2.755 2.333
Mean 3.55 0.07 0.03 18.44 14.50 2.87 1.69
Std Dev 0.82 0.02 0.02 16.07 16.40 0.67 0.70
For each individual, the mean and standard deviations for wave components for CD8 T cell activation is presented.
doi:10.1371/journal.pone.0021190.t005
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observations, we found evidence of complex oscillatory behavior in
these populations. This behavior was more evident among
individuals not receiving a protease-based regimen. This suggests
that the various measurements are linked to each other in an as yet
poorly defined mechanism, although the temporal changes might
be consistent with a previously hypothesized ‘‘predator-prey’’
association, as described below [27].
Our data regarding the relationship between CD4+ T cell
activation and CD4+ T cell counts is generally in agreement with
prior work in untreated HIV-infected persons. For example,
Catalfamo and colleagues reported that the degree of CD4+ T cell
activation (or proliferation) is driven by homeostatic responses and
that CD8+ T cell activation is mainly a direct pro-inflammatory
consequence of viral replication [28]. Of note, presently it is not
possible in these observational studies to clearly define the causal
pathway. Although some have argued that the higher levels of
CD4+ T cell activation in subjects with lower CD4+ T cell counts
reflects a homeostatic response to low CD4+ T cell counts [28],
others have argued that higher CD4+ T cell activation is
mechanistically involved in CD4+ T cell depletion. Support for
this latter perspective is based on several consistent observations,
including: (1) measures of T cell activation rather than viral load
predict outcome in the natural host of SIV [29], (2) measures of T
cell activation in humans predict subsequent disease outcome
independent of viral load [8,9,30], and (3) generalized T cell
activation in the absence of SIV/HIV infection can cause CD4+ T
cell but not CD8+ T cell depletion [31,32]. The striking and
consistent relationship between viral load and CD8+ T cell
Table 6. Spectral analysis estimated parameters for HIV viremia.
HIV Viremia
Patient Number of waves Mean Frequency Std Dev Mean Amplitude Std Dev Mean Phase Std Dev
2004 No oscillations
3025 4 0.086 0.059 1245.86 692.327 4.436 1.328
3035 4 0.013 0.018 505.27 438.186 1.785 1.175
3037 4 0.034 0.048 3086.03 1102.75 2.734 1.924
3040 4 0.052 0.032 2429.39 704.876 4.759 1.805
3042 2 0.092 0.039 2568.66 483.054 3.000 1.044
3077 5 0.099 0.0319 4333.25 5465.362 4.298 1.3959
3089 2 0.043 0.0521 5882.81 1411.156 5.943 0.1204
3102 No oscillations
3135 4 0.044 0.0366 8829.99 7456.89 2.727 0.8222
3153 4 0.086 0.0324 41015.96 26361 4.718 2.1039
Mean 3.67 0.06 0.04 7766.36 4901.73 3.822 1.30
Std Dev 1.00 0.03 0.01 12721.27 8431.66 1.322 0.61
For each individual, the mean and standard deviations for wave components for HIV viremia is presented.
doi:10.1371/journal.pone.0021190.t006
Table 7. Spectral analysis estimated parameters for CD4 T-cell activation.
CD4 T cell activation
Patient Number of waves Mean Frequency SD Mean Amplitude SD Mean Phase SD
2004 6 0.066 0.051 2.438 1.061 2.98 1.37
3025 7 0.059 0.042 4.61 2.475 3.216 1.906
3035 5 0.043 0.034 5.62 2.011 3.191 1.702
3037 2 0.043 0.034 6.18 4.994 3.678 0.965
3040 4 0.069 0.044 8.04 4.561 1.846 1.383
3042 3 0.092 0.027 5.54 1.823 4.219 2.062
3077 5 0.101 0.046 5.42 3.978 3.282 1.932
3089 4 0.053 0.042 3.53 1.48 2.449 2.095
3102 4 0.075 0.04 3.10 3.524 2.339 1.929
3135 4 0.052 0.028 4.27 2.184 2.677 2.826
3153 3 0.090 0.008 3.94 1.434 3.550 0.414
Mean 4.27 0.07 0.04 4.79 2.68 3.039 1.69
Std Dev 1.42 0.02 0.01 1.59 1.36 0.676 0.64
For each individual, the mean and standard deviations for wave components for CD4 T cell activation is presented.
doi:10.1371/journal.pone.0021190.t007
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activation observed in our study is consistent with a robust
literature suggesting that these two properties are highly associated
in untreated and treated disease [7,28]. Viral replication is almost
certainly causally associated with CD8+ T cell activation, as the
latter parameter decreases consistently in response to combination
therapy [33].
We observed no consistent association between replicative
capacity and viremia. This lack of an association may be due to
several factors, including the use of an assay that only incorporated
parts of the patient-derived viral genome. It is also possible (and
indeed we believe likely) that the true replicative capacity of the
virus in vivo may not directly predict viremia. Bonhoeffer, Coffin
and Nowak, for example, predicted that mutations which reduce
the capacity of the virus to infect its target cells would lead to
reduction in viremia, reduced CD4+ T cell death, expanded
numbers of CD4+ T cells and ultimately an increase in viremia
back towards the baseline level (with this increase supported by the
increased availability of target cells) [34]. Recently, in collabora-
tion with our group, Vaida and colleagues observed that
prospective treatment-mediated reductions in viral fitness resulted
had minimal effects on viremia but appeared to preserve CD4+ T
cells [3].
The oscillations that we have observed in a range of cell
populations are indicative of nonlinear dynamics and interactions
between the populations. Oscillations are found commonly in
many nonlinear dynamic systems, and the interactions between
HIV and the immune system are undoubtedly nonlinear [35,36].
There have been several studies that have noted this phenomenon.
Spouge, Shrager and Dimitrov describe oscillatory behavior of
HIV spread in tissue culture systems [37], while theoretical models
by Nowak and Bangham [38], Phillips et al [39] and Perelson,
Kirschner and De Boer [40] suggest oscillatory behavior may
occur in vivo as well. To our knowledge, ours is the first study that
demonstrates the presence of an oscillatory pattern using observed
longitudinal clinical data derived from a study designed in part to
address these issues.
A mechanistic model based on our data and prior studies is
needed to fully understand the significance of the oscillatory
associations between CD4+ T cell counts, viremia, and T cell
activation. Although such a model is outside the scope of this
paper, it is clear from our current data that, among reasonably
stable subjects with drug-resistant HIV, there exists complex cell/
virus interaction as indicated by the presence of sine waves at
multiple frequencies in the spectral analysis. The presence of two
and more frequencies of oscillation is a signature of more than one
equilibrium state between the virus and the cells of the immune
system. Furthermore, the existence of oscillations of high and low
frequencies within the same system is indicative of processes taking
place on different time scales. A variety of forces have been
identified as drivers of periodicity in natural systems. Dynamic
interactions between host and parasite populations cause oscilla-
tions in disease epidemics [41]. Climatic determinants have been
described as the force behind epidemics of dengue fever and
malaria [42,43,44]. Random noise is also capable of inducing
oscillations in deterministic systems [45]. Such systems are
commonly studied using spectral analysis, which is an important
tool in describing oscillatory behavior as it provides additional
Table 8. Spectral analysis estimated parameters for CD4 T cell count.
CD4 count
Patient Number of waves Mean Frequency SD Mean Amplitude SD Mean Phase SD
2004 2 0.026 0.022 29.93 17.371 3.921 3.328
3025 5 0.088 0.064 173.08 100.792 4.024 2.17
3035 5 0.082 0.039 41.82 25.996 2.702 2.03
3037 5 0.048 0.036 49.70 45.099 2.772 1.071
3040 4 0.045 0.033 94.78 57.969 3.909 1.803
3042 6 0.069 0.04 252.48 220.891 3.281 2.016
3077 3 0.054 0.031 107.63 78.17 2.178 2.56
3089 4 0.093 0.013 70.36 25.979 3.189 1.071
3102 3 0.082 0.01 41.22 17.746 5.017 1.258
3135 4 0.033 0.037 6636.00 7656 2.063 1.755
3153 4 0.081 0.044 157.81 106.193 3.628 1.762
Mean 4.09 0.06 0.03 695.89 759.29 3.335 1.89
Std Dev 1.14 0.02 0.01 1971.31 2288.15 0.881 0.66
For each individual, the mean and standard deviations for wave components for CD4 T cell counts is presented.
doi:10.1371/journal.pone.0021190.t008
Table 9. Parameters associated with log HIV viremia among a
subset of patients with partially controlled drug resistant
viremia using a non-linear mixed-effects model.
Effect Estimate
Standard
Error P
Intercept 0.0714 0.4032 0.863
Time (weeks) 0.00614 0.00947 0.1132
CD8 activation 0.8468 0.1739 0.0007
Baseline Viremia 0.6272 0.1171 0.0003
No protease inhibitor 0.2237 0.1128 0.0755
Cyclical component 20.0183 0.009 0.07
Cyclical component*No PI use 0.02522 0.011 0.0453
The model found evidence of an oscillatory signal in patients whose regimens
did not include a protease inhibitor.
doi:10.1371/journal.pone.0021190.t009
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insight into the complexity of system dynamics which could not be
gained from analysis solely in the time-domain.
One caveat is that this study is based on a small population of
patients who were selected because they had a steady-state viral
load on a partially suppressive stable regimen. Further, for the
spectral analysis and nonlinear mixed-models patients were
selected if they had at least 20 longitudinal observations. It was
necessary to have this many time points to be able to identify the
sometimes damped oscillatory behavior. Moreover, it is known
that co-morbidities such as cardiovascular disease and diabetes can
cause generalized immune activation. Although these patients did
not have a coronary heart disease or diabetes diagnosis, we did not
have data on markers that could indicate a preclinical condition.
Further we did not have data on other potential confounders such
as exposure to influenza, recent vaccinations or stress that could
have caused increases in immune activation. Further detailed
studies are needed. Although our study design does not allow for
strong conclusions regarding the cause and effect relationship of
activation and either viral load or CD4+ T cell counts, it does
provide novel insights into this relationship and suggests that it
may be altered by drug-resistant HIV. Along these lines,
Bonhoeffer and colleagues predicted that a treatment-related
decrease in viral fitness would result in a new dynamic between
viral load and target cells [27]. Specifically, any decrease in fitness
may act to preserve CD4+ T cell counts (due to reduction in
pathogenicity); these preserved CD4+ T cells could increase as a
consequence, although preservation of total body CD4+ T cells
may or may not be reflected in the number of circulating cells. The
critical role of target cell availability as a determinant of viral load
in treated disease has also been postulated as cause of viral blips
during treatment [46,47].
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